Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 3
2010 9
2011 19
2012 70
2013 99
2014 137
2015 172
2016 191
2017 250
2018 257
2019 267
2020 414
2021 474
2022 458
2023 443
2024 215

Text availability

Article attribute

Article type

Publication date

Search Results

3,028 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib Phosphate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Jan 5;79(2):6-9. doi: 10.1093/ajhp/zxab396. Am J Health Syst Pharm. 2022. PMID: 34894123 No abstract available.
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
Results A 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A 50% reduction in the total symptom score was observed in …
Results A 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the mo …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitini …
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib …
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. ...RESULTS: The primary end point was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group …
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. . …
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C, Nichols KE, Albeituni S. Keenan C, et al. Front Immunol. 2021 Feb 16;12:614704. doi: 10.3389/fimmu.2021.614704. eCollection 2021. Front Immunol. 2021. PMID: 33664745 Free PMC article. Review.
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Among the agents being tested is ruxolitinib, a potent inhibitor of the Janus Kinase (JAK) and Signal Transducer and Activation of Transcripti …
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Among the …
Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice.
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Bai Y, et al. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. eCollection 2020. Int J Biol Sci. 2020. PMID: 31929748 Free PMC article.
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment displayed less tubular injuries compared with those without Ruxolitinib treatment. ...
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment display …
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.
Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Appeldoorn TYJ, et al. Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31. Clin Pharmacokinet. 2023. PMID: 37000342 Free PMC article.
RESULTS: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics can be described with a two-compartment model and linear elimination. ...
RESULTS: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics …
Ruxolitinib.
Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R. Ajayi S, et al. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. Recent Results Cancer Res. 2018. PMID: 30069628
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. ...In PV, ruxolitinib effectively controls the hematocrit and reduces splenomegaly. ...
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. ...In …
Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S, Huo WX, Yang Y, Shen MZ, Mo XD. Fan S, et al. Front Immunol. 2022 Aug 4;13:954268. doi: 10.3389/fimmu.2022.954268. eCollection 2022. Front Immunol. 2022. PMID: 35990629 Free PMC article.
Ruxolitinib is an important treatment for steroid refractory graft-versus-host disease (SR-GVHD). ...The ORR, CRR, infection events, and myelosuppression were all comparable between children and adults with SR-GVHD. In summary, this study suggests that ruxolitinib i …
Ruxolitinib is an important treatment for steroid refractory graft-versus-host disease (SR-GVHD). ...The ORR, CRR, infection events, …
A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
Zhang Q, Zhao YZ, Ma HH, Wang D, Cui L, Li WJ, Wei A, Wang CJ, Wang TY, Li ZG, Zhang R. Zhang Q, et al. Blood. 2022 Jun 16;139(24):3493-3504. doi: 10.1182/blood.2021014860. Blood. 2022. PMID: 35344583 Free article.
All responders achieved their first response to ruxolitinib within 3 days. The response to ruxolitinib was significantly associated with the underlying etiology at enrollment (P = .009). ...Our study provides clinical evidence for ruxolitinib as a frontline a …
All responders achieved their first response to ruxolitinib within 3 days. The response to ruxolitinib was significantly assoc …
3,028 results